About: Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety
Creator	Petrovsky, Nikolai Cooper, Peter
Source	Elsevier; Medline; PMC
abstract	There is an ongoing need for new adjuvants to facilitate development of vaccines against HIV, tuberculosis, malaria and cancer, amongst many others. Unfortunately, the most potent adjuvants are often associated with toxicity and safety issues. Inulin, a plant-derived polysaccharide, has no immunological activity in its native soluble form but when crystallised into stable microparticles (delta inulin) acquires potent adjuvant activity. Delta inulin has been shown to enhance humoral and cellular immune responses against a broad range of co-administered viral, bacterial, parasitic and toxin antigens. Inulin normally crystallises as large heterogeneous particles with a broad size distribution and variable solubility temperatures. To ensure reproducible delta inulin particles with a consistent size distribution and temperature of solubility, a current Good Manufacturing Practice (cGMP) process was designed to produce Advax™ adjuvant. In its cGMP form, Advax™ adjuvant has proved successful in human trials of vaccines against seasonal and pandemic influenza, hepatitis B and insect sting anaphylaxis, enhancing antibody and T-cell responses while at the same time being safe and well tolerated. Advax™ adjuvant thereby represents a novel human adjuvant with positive effects on both humoral and cellular immunity. This review describes the discovery and development of Advax™ adjuvant and research into its unique mechanism of action.
has issue date	2015-11-01(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2015.09.030
bibo:pmid	26407920
has license	green-oa
sha1sum (hex)	031fb114a068c900631395c7be12bfb7655cacfb
schema:url	https://doi.org/10.1016/j.vaccine.2015.09.030
resource representing a document's title	Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety
has PubMed Central identifier	PMC4639457
has PubMed identifier	26407920
schema:publication	Vaccine
resource representing a document's body	covid:031fb114a068c900631395c7be12bfb7655cacfb#body_text
is schema:about of	named entity 'large' named entity 'Unfortunately' named entity 'positive' named entity 'heterogeneous' named entity 'malaria' named entity 'enhance' covid:arg/031fb114a068c900631395c7be12bfb7655cacfb named entity 'antibody' named entity 'viral' named entity 'Good Manufacturing Practice' named entity 'unique' named entity 'adjuvants' named entity 'toxicity' named entity 'inulin' named entity 'enhancing' named entity 'temperatures' named entity 'cancer' named entity 'human' named entity 'process' named entity 'inulin' named entity 'Inulin' named entity 'hepatitis' named entity 'HIV' named entity 'antigens' named entity 'malaria' named entity 'current Good Manufacturing Practice' named entity 'toxin' named entity 'adjuvants' named entity 'microparticles' named entity 'plant-derived' named entity 'solubility' named entity 'polysaccharide' named entity 'preclinical studies' named entity 'long-lived' named entity 'Th2' named entity 'beneficial effect' named entity 'inulin' named entity 'CD4' named entity 'colon cancer cells' named entity 'Inulin' named entity 'inulin' named entity 'Inulin' named entity 'antigen' named entity 'IFN-γ' named entity 'JEV' named entity 'hepatic' named entity 'inflammatory responses' named entity 'inulin' named entity 'inulin' named entity 'H5N1' named entity 'inulin' named entity 'adjuvant' named entity 'adjuvant' named entity 'insoluble' named entity 'vaccine' named entity 'pregnancy' named entity 'influenza vaccine' named entity 'inulin' named entity 'anti-influenza' named entity 'intraperitoneal' named entity 'polymers' named entity 'antigen' named entity 'inulin' named entity 'adverse effects' named entity 'cross-protective' named entity 'lung' named entity 'alpha or beta' named entity 'neutralizing antibody' named entity 'adjuvant' named entity 'SARS' named entity 'WNV' named entity 'Th1' named entity 'salts' named entity 'T-cell' named entity 'fructan' named entity 'adjuvant' named entity 'antigen' named entity 'tumour' named entity 'splenic' named entity 'adjuvant'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software